Phase 2 N=204 Randomized Triple-blind Treatment

Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence

Methamphetamine Dependence

Bottom Line

View on ClinicalTrials.gov: NCT00687713 ↗

Enrolled (actual)

204

Serious AEs

2.0%

Results posted

Feb 2017

Primary outcome: Primary: Number of Subjects Showing Abstinence — 14; 20 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Bupropion (Drug); Placebo (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: National Institute on Drug Abuse (NIDA)
Primary completion: May 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Subjects Showing Abstinence	14; 20	—
SECONDARY Treatment Success Among Subjects With 18 or Less Days of Methamphetamine Use	65; 76	—

Summary

This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.

Eligibility Criteria

Inclusion Criteria

Must have a DSM-IV diagnosis of methamphetamine dependence as determined by MINI
Must have at least 1 amphetamine or methamphetamine positive urine specimen after the start of screening and before randomization or provide information to verify recent use if a positive urine sample can't be obtained
Must report using methamphetamine for 29 days or less during the 30 day period prior signing consent using the timeline follow-back method
Must be willing and able to comply with study procedures
Must be able to verbalize and understand consent forms and provide written informed consent
Must be seeking treatment for methamphetamine dependence

Exclusion Criteria

Please contact study site for more information

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00687713). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.